VivoSeq
Oncology

Hematopoietic and Lymphoid Cell Neoplasm

42

Pipeline Programs↗

0

Active Trials↗

24

Companies Involved↗

Hematopoietic and Lymphoid Cell Neoplasm is a moderately active landscape with 42 programs across 24 companies. The most active players are Merck & Co., Iovance Biotherapeutics, Inc., Incyte. 20 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

56/100

Pipeline Velocity

0/100

Mech. Concentration

6/100

Completion Rate

50/100

Attrition Rate

50/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Merck & Co. logo

Merck & Co.

2 programs

Phase 1I

Iovance Biotherapeutics, Inc.

1 program

Phase 1Incyte logo

Incyte

1 program

Phase 1B

Bellicum Pharmaceuticals

1 program

Phase 1COMPASS Pathways logo

COMPASS Pathways

1 program

Phase 1H

Hyundai Pharmaceutical Co., LTD.

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

68%

Small molecule

27 of 40 classified programs — the dominant modality here.

33%ALL OTHERSMonoclonal antibody718%Protein / enzyme513%Antibody–drug conjugate13%

Small molecule leads; the ring shows all 40 classified programs, each share of the total. Modality classified for 98% of 42 pipeline programs.

Analysis

Trial Status

2

clinical trials

Completed1 · 50%
Terminated1 · 50%

Clinical Trials

Trial Activity

Phase II Trial of Salvage Radiation Therapy to Induce Systemic Disease Regression After Progression on Systemic Immunotherapy
Completed·MM.D. Anderson Cancer Center·Phase 2·NCT02710253·214 enrolled
Optimizing Immunosuppression for Steroid-Refractory Anti-PD-1/PD-L1 Pneumonitis
Terminated·ECOG-ACRIN Cancer Research Group·Phase 2·NCT04438382·1 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)